Canton Strategic Holdings (CNTN) Income from Continuing Operations (2021 - 2026)
Canton Strategic Holdings (CNTN) reported Income from Continuing Operations of 47343197.0 for Q1 2026, down 1762.66% on a YoY basis from 2847444.25 in Q1 2025, and down 1939.47% quarter-over-quarter from 2321353.0 in Q4 2025.
Canton Strategic Holdings (CNTN) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Canton Strategic Holdings has reported Income from Continuing Operations for 6 years, with the latest figure at 47343197.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 1762.66% year-over-year to 47343197.0; the trailing twelve-month figure through Mar 2026 stood at 53621541.0 (down 330.72% YoY), and the FY2025 full-year result was 35916250.0, down 194.45% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 47343197.0, down from 2321353.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1636854.0 in Q2 2022, with the low at 47343197.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 5065841.0 across 5 years, with a median of 2325057.0 in 2024.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations soared 44.63% — and 2026, when it slumped 1762.66%.
- Canton Strategic Holdings' Income from Continuing Operations stood at 1757682.0 in 2022, then tumbled by 40.74% to 2473777.0 in 2023, then slumped by 53.08% to 3786758.0 in 2024, then jumped by 38.7% to 2321353.0 in 2025, then plunged by 1939.47% to 47343197.0 in 2026.
- The last three Income from Continuing Operations figures came in at 47343197.0 (Q1 2026), 2321353.0 (Q4 2025), and 2101838.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - | -47.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.34 Mn |
| Dec 31, 2025 | -2.32 Mn |
| Sep 30, 2025 | -2.10 Mn |
| Jun 30, 2025 | -1.86 Mn |
| Mar 31, 2025 | -2.54 Mn |
| Dec 31, 2024 | -3.79 Mn |
| Sep 30, 2024 | -3.80 Mn |
| Jun 30, 2024 | -2.33 Mn |
| Mar 31, 2024 | -2.26 Mn |
| Dec 31, 2023 | -2.47 Mn |
| Sep 30, 2023 | -1.82 Mn |
| Jun 30, 2023 | -2.34 Mn |
| Mar 31, 2023 | -2.69 Mn |
| Dec 31, 2022 | -1.76 Mn |
| Sep 30, 2022 | -2.13 Mn |
| Jun 30, 2022 | -1.64 Mn |
| Mar 31, 2022 | -2.95 Mn |
| Dec 31, 2021 | -359,593.00 |
| Sep 30, 2021 | -777,113.00 |
| Jun 30, 2021 | -1.29 Mn |